Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Articles published by Secarna Pharmaceuticals GmbH & Co. KG
First Subject Dosed in Lipigon’s Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology Platform
May 31, 2022
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
April 12, 2022
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Secarna Pharmaceuticals' Partner Denali Therapeutics Exercises Option for LNAplusTM Antisense Oligonucleotide Development Program in Neurodegeneration
February 22, 2022
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
November 10, 2021
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Tickers
ACHL
Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases
October 26, 2021
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Secarna Pharmaceuticals has Initiated a Transnational Scientific Consortium to Identify New Biomarkers for Personalized Cancer Immunotherapy with ASOs
October 25, 2021
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field of Antisense Drug Discovery
September 02, 2021
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.